Biotech | April 06, 2026
Enveric Biosciences bags key US patent for mental health drug
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
New facility in Sector 51 offers advanced, affordable, and patient-centric dialysis services for NCR patients
Safety was equally impressive. ENV-294 was well tolerated
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
Hands-on clinical workshop in Bengaluru brings together neurologists, ENT specialists and physicians
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
Developed for today’s fast-paced, visually demanding lifestyles, the lenses are built on ZEISS NeurOptix technology
The SirPAD trial marks a significant milestone in vascular intervention, positioning MagicTouch PTA as a promising future alternative for PAD treatment
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
Subscribe To Our Newsletter & Stay Updated
